Analyst: Novo has a new blockbuster on their hands
If the combination drug IDegLira wins approval, Novo Nordisk could have a new global blockbuster on their hands, says analyst Frank H. Andersen. However, the rejection of Tresiba in the US has cut billions of its potential peak-sales.
by Stefan Singh Kailay
According to analyst Frank H. Andersen, Jyske Bank, Novo Nordisk can add billions to its corporate accounts in the future if the combination product – which the group submitted a European registration application for last week – wins approval.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
